Compare CSR & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSR | CYRX |
|---|---|---|
| Founded | 1970 | 1999 |
| Country | United States | United States |
| Employees | 349 | 1100 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 931.7M | 814.9M |
| IPO Year | N/A | 2008 |
| Metric | CSR | CYRX |
|---|---|---|
| Price | $57.68 | $16.26 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | ★ $69.80 | $13.31 |
| AVG Volume (30 Days) | 236.4K | ★ 436.2K |
| Earning Date | 05-04-2026 | 05-04-2026 |
| Dividend Yield | ★ 4.58% | N/A |
| EPS Growth | N/A | ★ 156.22 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $176,177,000.00 |
| Revenue This Year | $1.24 | $11.06 |
| Revenue Next Year | $2.72 | $8.45 |
| P/E Ratio | $62.27 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $52.00 | $7.61 |
| 52 Week High | $69.61 | $17.20 |
| Indicator | CSR | CYRX |
|---|---|---|
| Relative Strength Index (RSI) | 68.67 | 53.00 |
| Support Level | $54.07 | $14.55 |
| Resistance Level | $59.80 | $16.87 |
| Average True Range (ATR) | 1.21 | 0.58 |
| MACD | 0.76 | -0.07 |
| Stochastic Oscillator | 90.56 | 55.02 |
Centerspace is a real estate investment trust (REIT) that focuses on the ownership, management, acquisitions, redevelopment, and development of apartment communities. The company operates through a single reportable segment which includes the ownership, management, development, redevelopment, and acquisition of apartment communities and conduct their corporate operations from offices in Minot, North Dakota and Minneapolis, Minnesota.
CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.